Edgar Filing: Edge Therapeutics, Inc. - Form 4

Edge Therap Form 4	peutics, Inc.								
March 15, 2							OMB A	PPROVAL	
FORN Check th if no lon subject t	nis box		SECURITIES AND EXCHANGE COMMISS Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP				Expires:	ber: 3235-0287	
Section Form 4 Form 5 obligation may cor <i>See</i> Instr 1(b).	16. or Filed pur ons section 17(SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							
(Print or Type	Responses)								
Yaman Alpaslan Syr			2. Issuer Name and Ticker or Trading Symbol Edge Therapeutics, Inc. [EDGE]			5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (3. Date of Earliest Transaction (Cl				eck all applicable)		
((Month/Day/Year) 03/13/2017			Director 10% Owner X_ Officer (give title Other (specify below) V.P., Technical Ops. & Mfg.			
			If Amendment, Date Original led(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
(City)	(State)	(7:-)				Person			
1.Title of Security (Instr. 3)	2. Transaction Date	2A. Deemed Execution Date, any (Month/Day/Ye	if TransactionAd Code Di ar) (Instr. 8) (In Code V A	Securities cquired (A) of isposed of (E nstr. 3, 4 and (A) or mount (D)	or 5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	of, or Beneficia 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Kenninger. Ke	port on a separate fille		securities benefici	Persons w	vho res	pond to the colle ained in this forr		SEC 1474 (9-02)	

information contained in this form are not (9required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Edge Therapeutics, Inc. - Form 4



Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option, representing a right to purchase a total of 40,000 shares of Common Stock, will become exercisable on February 17, 2018,

(1) with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.